High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study

Research output: Contribution to journalArticle

Abstract

Purpose: The prognosis of metastatic/high-risk localized small round-cell tumors (SRCTs) treated conventionally is dismal. In this phase II study, we explored a high-dose chemotherapy (HD-CT) approach and analyzed the clinical significance of fusion transcripts detection. Patients and Methods: From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT. Local treatment (radiotherapy and/or surgery) was performed when possible. Molecular analysis was performed on peripheral-blood and leukapheresis products by reverse-transcriptase polymerase chain reaction. Results: Overall response (OR) was 65% (18 of 28), with 40% complete response and 25% partial response. According to histology, the OR rate was 86% in pPNET and 43% in both RMS DSRCT. With a median follow-up of 35 months, median overall survival was 16 months and median progression-free survival (PFS) was 10 months. PFS was statistically better in pPNET than other histologic types (P = .0045). No correlation was found between the fusion transcript and clinical outcome during follow-up. Furthermore, transcript detection in leukapheretic products was not of prognostic significance. Conclusion: Intensive HD-CT seems to enhance the response rate and survival when compared with conventional treatment in poor-prognosis pPNET. The poor results of this treatment in RMS and DSRCT do not support the inclusion of such an approach in these patient subsets. No definitive conclusions can currently be drawn concerning the clinical implications of the detection of fusion transcripts during treatment or follow-up.

Original languageEnglish
Pages (from-to)2181-2188
Number of pages8
JournalJournal of Clinical Oncology
Volume20
Issue number8
DOIs
Publication statusPublished - Apr 15 2002

Fingerprint

Peripheral Primitive Neuroectodermal Tumors
Desmoplastic Small Round Cell Tumor
Rhabdomyosarcoma
Prospective Studies
Drug Therapy
Disease-Free Survival
Neoplasms
Leukapheresis
Epirubicin
Ifosfamide
Induction Chemotherapy
Vincristine
Therapeutics
Reverse Transcriptase Polymerase Chain Reaction
Histology
Radiotherapy
Survival Rate
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{9a0aa24ecf024934814d76e8ff1adf70,
title = "High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study",
abstract = "Purpose: The prognosis of metastatic/high-risk localized small round-cell tumors (SRCTs) treated conventionally is dismal. In this phase II study, we explored a high-dose chemotherapy (HD-CT) approach and analyzed the clinical significance of fusion transcripts detection. Patients and Methods: From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT. Local treatment (radiotherapy and/or surgery) was performed when possible. Molecular analysis was performed on peripheral-blood and leukapheresis products by reverse-transcriptase polymerase chain reaction. Results: Overall response (OR) was 65{\%} (18 of 28), with 40{\%} complete response and 25{\%} partial response. According to histology, the OR rate was 86{\%} in pPNET and 43{\%} in both RMS DSRCT. With a median follow-up of 35 months, median overall survival was 16 months and median progression-free survival (PFS) was 10 months. PFS was statistically better in pPNET than other histologic types (P = .0045). No correlation was found between the fusion transcript and clinical outcome during follow-up. Furthermore, transcript detection in leukapheretic products was not of prognostic significance. Conclusion: Intensive HD-CT seems to enhance the response rate and survival when compared with conventional treatment in poor-prognosis pPNET. The poor results of this treatment in RMS and DSRCT do not support the inclusion of such an approach in these patient subsets. No definitive conclusions can currently be drawn concerning the clinical implications of the detection of fusion transcripts during treatment or follow-up.",
author = "Alexia Bertuzzi and Luca Castagna and Andrea Nozza and Vittorio Quagliuolo and Licia Siracusano and Monica Balzarotti and Silvana Compasso and Marco Alloisio and Parra, {Hector Soto} and Armando Santoro",
year = "2002",
month = "4",
day = "15",
doi = "10.1200/JCO.2002.08.033",
language = "English",
volume = "20",
pages = "2181--2188",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - High-dose chemotherapy in poor-prognosis adult small round-cell tumors

T2 - Clinical and molecular results from a prospective study

AU - Bertuzzi, Alexia

AU - Castagna, Luca

AU - Nozza, Andrea

AU - Quagliuolo, Vittorio

AU - Siracusano, Licia

AU - Balzarotti, Monica

AU - Compasso, Silvana

AU - Alloisio, Marco

AU - Parra, Hector Soto

AU - Santoro, Armando

PY - 2002/4/15

Y1 - 2002/4/15

N2 - Purpose: The prognosis of metastatic/high-risk localized small round-cell tumors (SRCTs) treated conventionally is dismal. In this phase II study, we explored a high-dose chemotherapy (HD-CT) approach and analyzed the clinical significance of fusion transcripts detection. Patients and Methods: From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT. Local treatment (radiotherapy and/or surgery) was performed when possible. Molecular analysis was performed on peripheral-blood and leukapheresis products by reverse-transcriptase polymerase chain reaction. Results: Overall response (OR) was 65% (18 of 28), with 40% complete response and 25% partial response. According to histology, the OR rate was 86% in pPNET and 43% in both RMS DSRCT. With a median follow-up of 35 months, median overall survival was 16 months and median progression-free survival (PFS) was 10 months. PFS was statistically better in pPNET than other histologic types (P = .0045). No correlation was found between the fusion transcript and clinical outcome during follow-up. Furthermore, transcript detection in leukapheretic products was not of prognostic significance. Conclusion: Intensive HD-CT seems to enhance the response rate and survival when compared with conventional treatment in poor-prognosis pPNET. The poor results of this treatment in RMS and DSRCT do not support the inclusion of such an approach in these patient subsets. No definitive conclusions can currently be drawn concerning the clinical implications of the detection of fusion transcripts during treatment or follow-up.

AB - Purpose: The prognosis of metastatic/high-risk localized small round-cell tumors (SRCTs) treated conventionally is dismal. In this phase II study, we explored a high-dose chemotherapy (HD-CT) approach and analyzed the clinical significance of fusion transcripts detection. Patients and Methods: From June 1997 to November 1999, 28 SRCT patients (median age, 26 years; 14 peripheral primitive neuroectodermal tumors [pPNETs], seven rhabdomyosarcomas [RMSs], and seven desmoplastic small round-cell tumors [DSRCTs]) received induction chemotherapy with ifosfamide, epirubicin, and vincristine followed by HD-CT. Local treatment (radiotherapy and/or surgery) was performed when possible. Molecular analysis was performed on peripheral-blood and leukapheresis products by reverse-transcriptase polymerase chain reaction. Results: Overall response (OR) was 65% (18 of 28), with 40% complete response and 25% partial response. According to histology, the OR rate was 86% in pPNET and 43% in both RMS DSRCT. With a median follow-up of 35 months, median overall survival was 16 months and median progression-free survival (PFS) was 10 months. PFS was statistically better in pPNET than other histologic types (P = .0045). No correlation was found between the fusion transcript and clinical outcome during follow-up. Furthermore, transcript detection in leukapheretic products was not of prognostic significance. Conclusion: Intensive HD-CT seems to enhance the response rate and survival when compared with conventional treatment in poor-prognosis pPNET. The poor results of this treatment in RMS and DSRCT do not support the inclusion of such an approach in these patient subsets. No definitive conclusions can currently be drawn concerning the clinical implications of the detection of fusion transcripts during treatment or follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0037089658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037089658&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.08.033

DO - 10.1200/JCO.2002.08.033

M3 - Article

C2 - 11956280

AN - SCOPUS:0037089658

VL - 20

SP - 2181

EP - 2188

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -